Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04513665 · ClinicalTrials.gov registry record · Phase 2

ZW25 in Women With Endometrial Cancers

A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
Phase 2
Development phase
16
Enrollment target

NCT04513665: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.

NCT04513665 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04513665, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
16 participants
Enrollment target

Study Summary

This study is being done to test the drug ZW25 and look at whether this drug is effective in women with HER2-overexpressed endometrial cancer or carcinosarcoma that has been treated in the past.

Interventions

  • DRUG ZW25

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2020-08-12
Est. Completion 2024-03-08
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

What the Registry Record Tells You About NCT04513665

The ClinicalTrials.gov registry entry for NCT04513665 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which ZW25 is the first listed.

NCT04513665 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04513665 about?

NCT04513665 is a clinical study titled "ZW25 in Women With Endometrial Cancers". This study is being done to test the drug ZW25 and look at whether this drug is effective in women with HER2-overexpressed endometrial cancer or carcinosarcoma that has been treated in the past.

What is the current status of trial NCT04513665?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2020-08-12. Estimated completion is 2024-03-08.

What interventions are being tested in trial NCT04513665?

The interventions under investigation include: ZW25 (DRUG).

Who is sponsoring clinical trial NCT04513665?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.